Sponsored By

Phillips-Medisize boosts production capacity in Finland

Phillips-Medisize Corp. (Hudson, WI) has added an automated production line at its plant in Kontiolahti, Finland, to meet the requirements of a new supply agreement for insulin pen components with Sanofi, a leader in diabetes treatment.The new pen is described as an easy-to-use disposable pen for the administration of lixisenatide. The finished device is made for the Japanese market.

PlasticsToday Staff

January 28, 2014

1 Min Read
Phillips-Medisize boosts production capacity in Finland

Phillips-Medisize Corp. (Hudson, WI) has added an automated production line at its plant in Kontiolahti, Finland, to meet the requirements of a new supply agreement for insulin pen components with Sanofi, a leader in diabetes treatment.

The new pen is described as an easy-to-use disposable pen for the administration of lixisenatide. The finished device is made for the Japanese market.

                Matt Jennings

The manufacturing involves injection molding, sophisticated assembly technology and tray handling robots, various measuring and testing systems as well as pad printing.

The assembly line was planned and installed by Phillips-Medisize, and includes multiple camera inspection points in the process. The company also built the tooling, which was principally designed and produced in the company's in-house tool shop.

Ina press release, Phillips-Medisize said it implemented the project, including all validations required, and delivered validated product in less than 12 months. The final pen assembly will be formally launched by Sanofi in Frankfurt, Germany.

"This agreement confirms our in-house tooling and automation expertise, combined with excellent project management capabilities are highly valued by our customers," said Matt Jennings, Phillips-Medisize President and CEO. "We will continue to develop our competency to offer them an even quicker service for their drug delivery device projects and are delighted to contribute to the rapid growth of the Sanofi diabetes treatment business."

In February 2013, Phillips-Medisize added another 6000 m² (64,583 s.f.) capacity to its Finnish facility. The expansion was driven by increased global demand for devices with precise dosage drug delivery requirements.

Sign up for the PlasticsToday NewsFeed newsletter.

You May Also Like